- **Name:** Scott C. Kogan, MD

- **Current Position:**

  Professor of Laboratory Medicine, University of California, San Francisco

- **Country:** USA

- **Educational Background:**

03/1986	A.B	Harvard University, Cambridge, MA - Biochemical Sciences, Summa cum laude
05/1991	M.D w/thesis	University of California, San Francisco - Medicine
06/1992		University of California, San Francisco - Resident, Laboratory Medicine
06/1993		University of California, San Francisco - Chief Resident, Laboratory Medicine
06/1997		University of California, San Francisco - Postdoctoral Research Fellow
06/1998		University of California, San Francisco - Hematopathology Fellow

- **Professional Experience:**

2000-2004	Chair, Hematopathology Subcommittee, Mouse Models of Human Cancers Consortium, NCI
2004-2007	Member, Scientific Committee on Clinical Laboratory, Hematology, American Society of Hematology
2008-2009	Chair, Scientific Committee on Hematopathology & Clinical Laboratory Hematology, ASH
2012-2015	Director, Hematopathology Fellowship, UCSF
2015-2017	Medical Director, UCSF Medical Center Clinical Laboratory, Parnassus Campus
1998-	Head, Clinical Coagulation Laboratory, UCSF
2012-	Chief, Clinical Hematology Laboratory, UCSF
2019-	Co-Director, Biorepository and Tissue Biomarker Technology Shared Resource, UCSF Helen Diller Family Comprehensive Cancer Center.

• Professional Organizations:

1998-	American Association for the Advancement of Science
1998-	American Society for Clinical Pathology
1998-	American Society of Hematology
2000-	International Society on Thrombosis and Hemostasis
2008-	American Association for Cancer Research
2014-	College of American Pathology

• Main Scientific Publications:

1. Dr. Scott Kogan has been active in advancing understanding of acute leukemias through the use of animal models, including the pathogenesis and treatment of acute promyelocytic leukemia.

   a. Keeshan K, Vieugue P, Chaudhury S, Rishi L, Gaillard C, Liang L, Garcia E, Nakamura T, Omidvar N, **Kogan SC**. Cooperative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveal C/EBPα as a common target of TRIB1 and PML/RARA. Haematologica. 2016 Oct;101(10):1228-1236. PMCID: PMC5046652
   b. Gaillard C, Tokuyasu TA, Rosen G, Sotzen J, Vitaliano-Prunier A, Roy R, Passegue E, de Thé H, Figueroa ME, and **Kogan SC.** Transcription and methylation analysis of preleukemic promyelocytes indicate a dual role for PML/RARA in leukemia initiation. Haematologica. 2015 Aug;100(8):1064-75. PMID: 26088929. PMCID: PMC5004423.
   c. Sternsdorf, T; Phan, V; Maunakea, ML; Ocampo-Bayuga, C; Sohal, J; Silletto, A; Galimi, F; LeBeau, MM; Evans, RM; **Kogan, SC**. Forced Retinoic Acid Receptor alpha Homodimers Prime Mice for APL-like Leukemia. Cancer Cell, 2006, 9:81-94
   d. Brown, DE*; **Kogan, SC***; Lagasse, E; Weissman, IL; Alcalay, M; Pelicci, P; Atwater, S; Bishop, JM. A PML-RARA Transgene Initiates Murine Acute Promyelocytic Leukemia. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:2551-2556. *These authors contributed equally to this work.

2. Dr. Scott Kogan has contributed to our understanding the use of targeted therapeutics in Hematopoietic neoplasms, including agents that target FLT and MYC.

   a. Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, Lowe SW, Goga A, **Kogan SC**. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015;76:35-46. PMID: 25956709; PMCID: PMC4485702.
   b. Smith CC, Lasater EA, Lin KC, Wang Q, McCreery MQ, Stewart WK, Damon LE, Perl AE, Jeschke GR, Sugita M, Carroll M, **Kogan SC**, Kuriyan J, Shah NP. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A. 2014; 111:5319-24. PMID: 24623852. PMCID: PMC3986131
   c. Lee, BD; Sevcikova, S; **Kogan SC**. Dual treatment with FLT3 inhibitor SU11657 and doxorubicin increases survival of leukemic mice. Leukemia Research, 2007, 31:1139-1142.
   d. Sohal, J; Phan, VT; Chan, PV; Davis, EM; Patel, B; Kelly, LM; Abrams, T; O'Farrell, AM; Gilliland, DG; LeBeau, MM; **Kogan, SC**. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood, 2003, 101: 3188-3197.

3. Dr. Scott Kogan has made numerous contributions as a collaborating pathologist to investigations of hematopoietic neoplasms. A few of the publications to which Dr. Kogan has contributed in this capacity are listed here:

   a. Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, **Kogan S**, Salomonis N, Figueroa ME, Grimes HL. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discov. 2016;6:501-15. PMID: 27016502; PMCID: PMC4861898.
   b. Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, **Kogan SC**, Lowe SW. Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet. 2015; 47:539-43. PMID: 25822087. PMCID: PMC4414804.
   c. Zuber, J; Shi, J; Wang, E; Rappaport, AR; Herrmann, H; Sison, EA; Magoon, D; Qi, J; Blatt, K; Wunderlich, M; Toylor, MJ; Johns, C; Chicas, A; Mulloy, JC; **Kogan, SC**; Brown, P; Valent, P; Bradner, JE; Lowe, SW; Vakoc, CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478:524-528.
   d. Premsrisut, PK; Dow LE; Kim, SY; Camiolo, M; Malone, CD; Miething, C; Scuoppo, C; Zuber, J; Dickins, RA; **Kogan, SC**; Shroyer, KR; Sordella, R; Hannon, GJ; Lowe SW. A rapid and scalable system for studying gene function in mice using condidtional RNA interference. Cell, 2011, 145:145-158.

4. Dr. Scott Kogan made early important contributions to the use of polymerase chain reaction technology for the diagnosis of genetic disease and the identification of novel genetic mutations.

a. Kogan SC; Doherty M; Gitschier J. An Improved Method for Prenatal Diagnosis of Genetic Diseases by Analysis of Amplified DNA Sequences: Application to Hemophilia A. New England Journal of Medicine 1987, 317:985-990.
b. Kogan S; Gitschier J. Mutations and a Polymorphism in the Factor VIII Gene Discovered by Denaturing Gradient Gel Electrophoresis. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:2092-2096.
c. Gitschier J; Kogan S; Levinson B; Tuddenham EG. Mutations of Factor VIII Cleavage Sites in Hemophilia A. Blood 1988, 72:1022-1028.